share_log

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

2022 年 9 月 12 日的重要生物技術催化劑——最後一天摘要
Benzinga Real-time News ·  2022/09/12 18:32
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics' (NASDAQ:MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC). Mersana shares traded as high as 1.79 percent, in a range of $7.48 to $7.94 on day volume of 1.34 million shares, closed regular trading session at $7.48. The company shares traded at $7.40, down 1.07 percent in the after-hours trading session.
美國食品和藥物管理局已批准默薩納治療公司(納斯達克代碼:MRSN)的主要候選藥物XMT-1660用於治療晚期或轉移性三陰性乳腺癌(TNBC)的成年患者。Mersana股價一度高達1.79%,在7.48美元至7.94美元的區間內,當日成交量為134萬股,常規交易時段收盤報7.48美元。該公司股價為7.40美元,在盤後交易中下跌1.07%。
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals' (NASDAQ:ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome...
美國食品和藥物管理局已經接受了阿卡迪亞製藥公司(納斯達克...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論